AN estimated 10 million hepatitis C patients in the country may hear the good news soon. A life-saving drug to be administered orally to such patients is expected to be cleared for distribution next week, long after it got the approval of the Drug Regulatory Authority of Pakistan. The matter has been pending with the Federal Ministry of Health Services Regulations and Coordination for the last three months, which somehow could not take out the time to give a formal nod to the medicine called Sovaldi. Whereas doctors have prescribed the tablet to a few thousand suffering Pakistanis in anticipation of its availability on the local market, one distribution company has been selected for its supply. The company is going to buy it from the United States. It was initially in competition with many other aspiring distributors, but managed to convince DRAP that it had the right combination of price and quality.
Read more... Labels: Exclusivity Deals, Pakistan, Sovaldi